<DOC>
	<DOCNO>NCT00954915</DOCNO>
	<brief_summary>The purpose study determine whether teplizumab safe administer subcutaneously ( needle skin ) subject psoriasis . The study also evaluate long teplizumab stay blood long take leave body , high dose safely give , whether improves psoriasis .</brief_summary>
	<brief_title>Safety Study Monoclonal Antibody Teplizumab ( MGA031 ) Subjects With Moderate More Severe Psoriasis</brief_title>
	<detailed_description>This study test hypotheses therapeutic modulation T-cell function teplizumab well tolerated subject moderate severe psoriasis , treatment ameliorates immunopathology psoriasis . This study evaluate safety , pharmacokinetics ( PK ) , pharmacodynamics ( PD ) subcutaneous ( SC ) administration 6 day . Once SC maximum tolerate dose identify , dose administer cohort subject intravenous comparison PK PD .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Chronic plaque psoriasis present 6 month involve least 10 % Body Surface Area ( BSA ) . Baseline LSPGA score moderate great severity . Weight &lt; = 125 kg ( 276 lb ) BSA &lt; = 2.5 m^2 . Clinically significant flare psoriasis 12 week enrollment . Guttate , erythrodermic , palmoplantar , pustular ( von Zumbusch ) psoriasis Orally administer systemic psoriasis therapy phototherapy within previous 4 week ; topical psoriasis treatment within previous 2 week enrollment . Prior administration biologic agent/monoclonal antibody within 12 week enrollment 5 halflives agent , whichever great . Prior otelixizumab , OKTÂ®3 , teplizumab . Treatment within last 30 day nonbiologic drug device receive regulatory approval indication time study entry unwilling forgo experimental treatment teplizumab study . Treatment live vaccine within 8 week enrollment study ; vaccination antigen kill organism study , within 8 week enrollment , 8 week dose . Evidence active infection . Positive IgM test hepatitis A . History positive test hepatitis B , C , D. History positive test HIV . Are immunocompromised , recent current serious systemic local infection , clinical radiological evidence active tuberculosis , evidence latent TB infection . History chronic liver disease , peripheral vascular disease , cerebrovascular disease , cardiovascular disease , epilepsy . Current serious unstable illness allergy . Clinically significant laboratory abnormality . Presence serological reactivity teplizumab ( subject previously treat therapeutic antibody ) . Clinically significant ECG abnormality .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>chronic plaque psoriasis</keyword>
	<keyword>psoriatic arthritis</keyword>
</DOC>